Exponent CEO exercises options, sells 7,821 shares
Exponent Inc. President & CEO Catherine Corrigan reported a series of option exercises combined with share sales.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
Exponent Inc. President & CEO Catherine Corrigan reported a series of option exercises combined with share sales. On March 16 and April 15, she exercised options covering a total of 11,211 shares of common stock at exercise prices of $25.405 and $29.05 per share.
Across the same dates, she sold 7,821 shares in open-market transactions at prices around $67.49–$67.70 per share and retained the remainder. Following these transactions, Corrigan holds 104,359 shares of Exponent common stock directly.
Insider Trade Summary 10b5-1
Exercise and sale activity reported; no spread calculated
Exercise and Sale
12 txns
Insider
Corrigan Catherine
Role
President & CEO
Sold
7,821 shs ($529K)
Approx. gross sale proceeds
$529K
Approx. exercise cost
$302K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Non-Qualified Stock Option (right to buy) | 3,225 | $0.00 | $0.00 |
| Exercise | Non-Qualified Stock Option (right to buy) | 2,380 | $0.00 | $0.00 |
| Exercise | Common Stock | 3,225 | $25.405 | $82K |
| Sale | Common Stock | 2,212 | $67.6964 | $150K |
| Exercise | Common Stock | 2,380 | $29.05 | $69K |
| Sale | Common Stock | 1,697 | $67.6964 | $115K |
| Exercise | Non-Qualified Stock Option (right to buy) | 3,226 | $0.00 | $0.00 |
| Exercise | Non-Qualified Stock Option (right to buy) | 2,380 | $0.00 | $0.00 |
| Exercise | Common Stock | 3,226 | $25.405 | $82K |
| Sale | Common Stock | 2,214 | $67.4882 | $149K |
| Exercise | Common Stock | 2,380 | $29.05 | $69K |
| Sale | Common Stock | 1,698 | $67.4882 | $115K |
Holdings After Transaction:
Non-Qualified Stock Option (right to buy) — 15,969 contracts (Direct);
Common Stock — 104,359 shares (Direct)
Footnotes (2)
- F1. The stock option becomes exercisable in four equal annual installments.
- F2. Not applicable.
Key Figures
Options exercised: 11,211 shares
Shares sold: 7,821 shares
Exercise prices: $25.405 and $29.05 per share
+2 more
5 metrics
Options exercised
11,211 shares
Total derivative exercises reported in transactionSummary
Shares sold
7,821 shares
Open-market sales of common stock reported in transactionSummary
Exercise prices
$25.405 and $29.05 per share
Non-qualified stock option conversion or exercise prices
Sale prices
$67.4882 and $67.6964 per share
Prices for open-market sales of common stock
Shares after transactions
104,359 shares
Direct common stock ownership following latest reported transaction
Key Terms
Non-Qualified Stock Option, open-market sale, Exercise or conversion of derivative security, total_shares_following_transaction
4 terms
Non-Qualified Stock Option financial
"security_title": "Non-Qualified Stock Option (right to buy)""
A non-qualified stock option (NSO) is a contract that lets an employee or service provider buy company shares at a fixed price for a set period, like a voucher to purchase stock later at today’s price. It matters to investors because exercising NSOs creates ordinary income for the holder and can increase share count, affecting a company’s earnings and ownership mix; think of it as a future sale that can dilute existing shareholders and has immediate tax consequences for the recipient.
open-market sale financial
"transaction_action": "open-market sale""
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
Exercise or conversion of derivative security financial
"transaction_code_description": "Exercise or conversion of derivative security""
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Exponent (EXPO) CEO Catherine Corrigan do in this Form 4?
Catherine Corrigan exercised stock options to acquire shares and sold some of the resulting common stock. She combined option exercises with open-market sales, increasing her direct holdings overall while generating cash from a portion of the exercised shares.
How many Exponent (EXPO) options did the CEO exercise?
She exercised options covering a total of 11,211 shares of Exponent common stock. The options had exercise prices of $25.405 and $29.05 per share, reflecting previously granted non-qualified stock options vesting in installments.
What are Catherine Corrigan’s Exponent (EXPO) holdings after these trades?
After completing the option exercises and share sales, Catherine Corrigan directly holds 104,359 shares of Exponent common stock. This figure comes from the post-transaction ownership numbers disclosed for her common stock holdings in the Form 4.
Were these Exponent (EXPO) transactions option exercises or open-market buys?
The acquisitions reported were option exercises, not open-market purchases. Corrigan exercised non-qualified stock options with exercise prices of $25.405 and $29.05, then sold part of the acquired common stock in open-market transactions at significantly higher market prices.
Do the Exponent (EXPO) Form 4 footnotes change how to view these trades?
The footnotes state the stock options become exercisable in four equal annual installments and note that some items are not applicable. They do not shift ownership to another entity or disclaim authority, so the transactions are attributed directly to Catherine Corrigan.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates